SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master, GREGG THE GREEK, NeverSettle
Search This Board: 
Last Post: 5/27/2017 9:24:50 PM - Followers: 74 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
GALT News: Statement of Changes in Beneficial Ownership (4) 05/24/2017 09:40:24 AM
GALT News: Securities Registration Statement (simplified Form) (s-3) 05/19/2017 04:17:57 PM
GALT News: Current Report Filing (8-k) 05/19/2017 04:12:46 PM
GALT News: Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update 05/15/2017 08:30:00 AM
GALT News: Current Report Filing (8-k) 05/15/2017 08:23:22 AM
PostSubject
#3134   Right now GALT is in the drivers seat RyGuy 05/27/17 09:24:50 PM
#3133   I picked up more Monday and am pleasantly rickyricks 05/27/17 06:16:30 PM
#3132   I think your analysis is spot on but Chess Master 05/26/17 08:07:08 PM
#3131   Not getting to $10 without either a major gss2003 05/26/17 06:32:34 PM
#3130   Article on GALT... RyGuy 05/26/17 03:45:03 PM
#3129   GALT moving back up nicely today RyGuy 05/26/17 02:39:53 PM
#3128   Been watching some 1.16s sail away Bearly Bullish 05/26/17 02:36:10 PM
#3127   Oversold from scared traders. Now GALT begins progressing RyGuy 05/26/17 01:37:53 PM
#3126   Yup, he went all in !!!!!! Coolec78 05/25/17 12:45:27 PM
#3125   did you see them yet? got a link Chess Master 05/24/17 11:07:26 PM
#3124   INSIDER Buying! I know its small but Chess Master 05/24/17 11:05:56 PM
#3123   GALT buy 2.3201 stocktrademan 05/24/17 12:09:50 PM
#3122   Galecto results are 2 days old, not sure gss2003 05/24/17 05:59:09 AM
#3120   Thank you for challenging him. Biotech is Chess Master 05/23/17 10:37:01 PM
#3119   Not so fast. You need to cut Chess Master 05/23/17 10:28:11 PM
#3118   I love how you say "they have 15 RyGuy 05/23/17 07:47:17 PM
#3117   According to the GALT filing, they have over biotech2010 05/23/17 06:59:21 PM
#3116   Galecto’s Inhaled TD139 Effective, Safe in Treating IPF FLGuy2017 05/23/17 04:49:49 AM
#3115   It was an over reaction but way less Chess Master 05/23/17 12:37:13 AM
#3114   This will head back up, as people realize RyGuy 05/22/17 05:34:55 PM
#3113   Completely over reaction by the market on GALT. RyGuy 05/22/17 11:40:03 AM
#3112   Uihlein isnt selling at all. It is Chess Master 05/22/17 09:22:52 AM
#3111   The NASH CX study is blinded but the sokol 05/22/17 08:49:48 AM
#3110   Doesn't it say Ullhein is selling for a gss2003 05/22/17 07:38:52 AM
#3109   You are not a bad guy but your Chess Master 05/22/17 04:11:34 AM
#3108   I'm not the bad guy in this story, biotech2010 05/22/17 02:36:22 AM
#3107   The only thing GALT needs cash for are Chess Master 05/21/17 07:24:44 PM
#3106   Galt needs cash. If you go to rickyricks 05/21/17 07:15:02 PM
#3105   Where do I start with your post. Chess Master 05/21/17 06:37:48 PM
#3104   Thanks for explaining. As usual much of what JERZYATP1 05/21/17 04:16:55 PM
#3103   I would just like to see someone else biotech2010 05/21/17 02:28:42 AM
#3102   Other than hedging with some call options which JERZYATP1 05/21/17 01:03:55 AM
#3101   Dream cancer trial. Mrk + Blcm + adap rickyricks 05/20/17 10:14:34 PM
#3100   look at GILD yahoo board before you throw rickyricks 05/20/17 10:00:41 PM
#3099   SMC gss2003 05/20/17 09:10:30 PM
#3098   This gave me the biggest laugh I've ever biotech2010 05/20/17 05:29:16 PM
#3097   ATM is only $30M of the $100M gss2003 05/20/17 05:12:22 PM
#3096   deja vu - March 21, 2014 - of jmh0602 05/20/17 05:08:52 PM
#3095   Also, read the PR closely where they mention gss2003 05/20/17 04:40:41 PM
#3094   Also, read the PR closely where they mention gss2003 05/20/17 04:40:40 PM
#3093   If they have the money to get through gss2003 05/20/17 03:49:15 PM
#3092   That's impossible because it's a double blind study, biotech2010 05/20/17 01:04:14 PM
#3091   There is other explanation. Corporate greed. And this Coolec78 05/20/17 09:22:18 AM
#3090   I, of course, am only speculating. Maybe sokol 05/20/17 08:30:30 AM
#3089   Why do they need this offering now? Traber Coolec78 05/19/17 07:33:53 PM
#3088   Has nothing to do with the offering price. Oddjob 05/19/17 05:30:17 PM
#3087   Uihlein selling just under 2,000,000 shares at a biotech2010 05/19/17 04:27:37 PM
#3086   Ok, maybe this is a long shot, but goingforittoday 05/13/17 05:50:53 PM
#3085   Any thoughts/leaks about tomorrow's earnings? Coolec78 05/12/17 12:20:07 AM
#3084   They could vary for indications. GR-MD-02 is in gss2003 04/30/17 01:47:20 PM
PostSubject